Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 14;25(30):4199-4212.
doi: 10.3748/wjg.v25.i30.4199.

Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis

Xiao-Na Liu  1 , Dan-Ni Cui  1 , Yu-Fang Li  1 , Yun-He Liu  1 , Gang Liu  1 , Lei Liu  2
Affiliations
Review

Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis

Xiao-Na Liu et al. World J Gastroenterol. .

Abstract

The huge prognostic difference between early and late stage hepatocellular carcinoma (HCC) is a challenging diagnostic problem. Alpha-fetoprotein is the mostly widely used biomarker for HCC used in the clinic, however it's sensitivity and specificity of is not optimal. The development and application of multiple biotechnologies, including next generation sequencing, multiple "omics" data, that include genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics has been used for HCC diagnostic biomarker screening. Effective biomarkers/panels/models have been identified and validated at different clinical levels. A large proportion of these have a good diagnostic performance for HCC, especially for early HCC. In this article, we reviewed the various HCC biomarkers derived from "omics" data and discussed the advantages and disadvantages for diagnosis HCC.

Keywords: Circulating tumor DNA; Circulating tumor cells; Diagnosis; Exosomes; Hepatocellular carcinoma; Metabolomics; Protein; RNA.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Multiple “Omics” data-based diagnostic biomarker for hepatocellular carcinoma. Circulating tumor cells, circulating tumor DNA, exsomes, transcriptomics, proteomics, metabolomics and intestinal microorganisms provide new non-invasive candidates diagnostic biomarkers for hepatocellular carcinoma. HCC: Hepatocellular carcinoma; CTCs: Circulating tumor cells; ctDNA: Circulating tumor DNA.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140–2151. - PMC - PubMed
    1. Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma: Epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras (1992) 2013;59:514–524. - PubMed
    1. Ružić M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brkić S, Abenavoli L. Hepatitis C virus-induced hepatocellular carcinoma: A narrative review. Panminerva Med. 2018;60:185–191. - PubMed
    1. Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett. 2018;412:283–288. - PubMed

MeSH terms

Substances